Cardiology journal最新文献

{"title":"Treatment of dyslipidemia in Poland - common diagnostics, early combined therapy. Expert position statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. 5th Declaration of Sopot.","authors":"Marcin Wełnicki, Iwona Gorczyca-Głowacka, Agnieszka Kapłon-Cieślicka, Maciej Janiszewski, Jarosław D Kasprzak, Przemysław Leszek, Anna Tomaszuk-Kazberuk, Maria Łukasiewicz, Mariusz Tomaniak, Stanisław Surma, Agnieszka Mickiewicz, Krzysztof Narkiewicz, Miłosz Jaguszewski, Zbigniew Krasiński, Daniel Śliż, Artur Mamcarz, Filip M Szymański, Marcin Barylski, Beata Wożakowska-Kapłon, Krzysztof J Filipiak","doi":"10.5603/cj.103680","DOIUrl":"https://doi.org/10.5603/cj.103680","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of an antibacterial envelope on cardiac implantable device-related infection - A real-world analysis from a tertiary center.","authors":"Nadine Molitor, Vera Graup, Daniel Hofer, Pascal Rüegg, Deniza Avdi, Ardan M Saguner, Alexander Breitenstein, Jan Steffel","doi":"10.5603/cj.100458","DOIUrl":"https://doi.org/10.5603/cj.100458","url":null,"abstract":"<p><strong>Background: </strong>Infections related to cardiac implantable electronic devices (CIED) are associated with significant morbidity and mortality. Antibiotic-eluting envelopes have been introduced as a technology to prevent CIED infections. The aim of this study was to evaluate the effectiveness of the antibacterial envelope in the real-world population of a tertiary center.</p><p><strong>Methods: </strong>This cohort study includes consecutively enrolled patients undergoing a device procedure from 01/2014 to 12/2020 at the University Hospital in Zurich. During period A (01/2014-12/2019) antibacterial envelopes were not used, whereas during period B (01/2020-12/2020) antibacterial envelopes were used in all device interventions. Follow-up was conducted by assessing all available patient records from patient visits and hospitalization.</p><p><strong>Results: </strong>1757 patients (male 70.5%, mean age 67.1 ± 16 years), were analyzed during a follow-up of 24 months. In 302 patients (17.2%) an antibacterial envelope was used. The overall occurrence of a device infection was low (n = 15, 0.85%). Factors that were associated with the incidence of an infection were not undergoing a primary implantation procedure (p = 0.024) and a CRT-P/D intervention (p = 0.022). There was no difference in the rate of infection between patients in whom a bacterial envelope was implanted vs. those in whom it was not used (0.6 vs. 0.9%, p = 0.693).</p><p><strong>Conclusion: </strong>In a contemporary cohort of consecutive, unselected patients undergoing a device intervention at a large tertiary care center, the rate of device infection was low and not significantly different with vs. without the use of an antibacterial envelope. The data have important practical as well as economic implications for physicians performing such procedures.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early treatment with inhibitors of P2Y12 receptor in patients with ST-segment elevation myocardial infarction - 2023 ESC recommendations and scientific evidence. Is clinical evidence sufficient to suggest a move towards precision medicine? The ELECTRA-SIRIO 2 investigators' viewpoint.","authors":"Jacek Kubica, Piotr Adamski, Jolita Badariene, Marc Bonaca, Piotr Buszman, Rahima Gabulova, Robert Gajda, Tobias Geisler, Robert Gil, Diana A Gorog, Paul A Gurbel, Tomasz Hajdukiewicz, Bartosz Hudzik, Stefan James, Young-Hoon Jeong, Adam Kern, Wacław Kochman, Aldona Kubica, Wiktor Kuliczkowski, Przemysław Magielski, Piotr Niezgoda, Małgorzata Ostrowska, Paolo Raggi, Uzeyir Rahimov, Grzegorz Skonieczny, Jolanta M Siller-Matula, Giuseppe Specchia, Łukasz Szarpak, Paweł Szymański, Udaya Tantry, Julia Umińska, Eliano Pio Navarese","doi":"10.5603/cj.99973","DOIUrl":"https://doi.org/10.5603/cj.99973","url":null,"abstract":"<p><p>The 2023 ESC guidelines changed previously recommended a strategy of early treatment in patients with STEMI. Pre-treatment with a P2Y12 receptor inhibitor may be considered in patients undergoing a primary PCI strategy (Class IIb, Level of evidence B). However, the available scientific evidence justifies a personalized approach differentiating the indications for pre-treatment with oral P2Y12 receptor inhibitors depending on the concomitant administration of opioids. In our opinion, in patients undergoing primary PCI not treated with opioids, pre-treatment with an oral P2Y12 receptor inhibitor should be applied, while in patients undergoing primary PCI treated with opioids, pre-treatment with an oral P2Y12 receptor inhibitor should be considered.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventing chronic heart failure and improving survival after transcatheter aortic valve implantation in patients with the need for permanent pacemaker implantation: Rationale and design of the physiologic cardiac pacing to prevent left ventricular dysfunction post transcatheter aortic valve implantation (PACE-4-TAVI) trial.","authors":"Danuta Łoboda, Rafał Gardas, Tomasz Soral, Radosław Gocoł, Damian Hudziak, Dariusz Jagielski, Jerzy K Wranicz, Jarosław Kaźmierczak, Jacek Lelakowski, Przemysław Mitkowski, Grzegorz Smolka, Wojciech Wojakowski, Krzysztof S Gołba","doi":"10.5603/cj.100726","DOIUrl":"https://doi.org/10.5603/cj.100726","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcatheter aortic valve implantation reduces plasma concentrations of TMAO and indoxyl sulfate: A prospective, multicenter cohort study.","authors":"Aleksandra Gąsecka, Marcelina Gniot, Bogna Rajewska, Weronika Dykacz, Weronika Kisielewska, Ewelina Błażejowska, Jakub M Zimodro, Marcin Grabowski, Bartosz Rymuza, Zenon Huczek, Janusz Kochman, Radosław Wilimski, Mariusz Kuśmierczyk, Jan Budzianowski, Jarosław Hiczkiewicz, Anna Olasińska-Wiśniewska, Marek Grygier, Krzysztof J Filipiak, Marcin Ufnal","doi":"10.5603/cj.102844","DOIUrl":"https://doi.org/10.5603/cj.102844","url":null,"abstract":"<p><strong>Background: </strong>Intestinal microbial metabolites, such as trimethylamine-N-oxide (TMAO) and indoxyl sulfate (IS), have been suggested as markers for the progression of aortic stenosis (AS). However, the impact of transcatheter aortic valve implantation (TAVI) on these intestinal bacterial metabolites has not been evaluated in a multicenter clinical study. The aim of this study was to determine the effect of TAVI on plasma levels of intestinal bacterial metabolites and to assess the predictive value of these metabolites for major adverse cardiovascular events (MACE) following TAVI. M: ETHODS: Consecutive patients with AS referred for TAVI were enrolled in this study. Blood samples were collected one day before TAVI and at hospital discharge. The concentrations of intestinal microbial metabolites were measured using ultra performance liquid chromatograph coupled with a mass spectrometer.</p><p><strong>Results: </strong>Plasma levels of TMAO and IS decreased after TAVI, compared to baseline (p ≤ 0.004 for all). Among 128 patients included in the study, 21 patients (16.4%) developed MACE during the median follow-up time of 404 days. Baseline plasma IS level was higher in patients with MACE, compared to those without MACE (p = 0.001). Increased baseline IS level predicted MACE with 75.0% sensitivity and 74.3% specificity independent of other clinical variables (OR 14.264, 95% CI 3.442-59.117, p < 0.001) and decreased the chance of event-free survival (plog rank < 0.001).</p><p><strong>Conclusions: </strong>Plasma concentrations of TMAO and IS decreased after TAVI, compared to baseline. Elevated plasma IS levels were associated with a 14-fold increase in the odds of post-TAVI MACE during a median follow-up period of 404 days.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of endomyocardial biopsy for surveillance of cardiac allograft rejection: time to move on?","authors":"Roberto Gómez-Sánchez, Carlos Ortiz-Bautista, Javier Castrodeza, Zorba Blázquez-Bermejo, Eduardo Zataraín-Nicolás, Adolfo Villa, Ricardo Sanz-Ruiz, Jaime Elízaga, Javier Bermejo","doi":"10.5603/cj.99019","DOIUrl":"https://doi.org/10.5603/cj.99019","url":null,"abstract":"","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The utility of brain biomarkers in predicting survival and neurological outcomes in pediatric patients after cardiac arrest: A systematic review and meta-analysis.","authors":"Halla Kamińska, Krzysztof Kurek, Michał Zembala, Sagar Galwankar, Monika Tomaszewska, Shraddha Singh, Nicola Luigi Bragazzi, Michał Pruc, Basar Cander, Francesco Chirico, Amelia Rizzo, Jacek Kubica, Ayman El-Menyar, Anne Lepetit, Pawel Patrzylas, Zubaid Rafique, W Frank Peacock, Łukasz Szarpak","doi":"10.5603/cj.103883","DOIUrl":"https://doi.org/10.5603/cj.103883","url":null,"abstract":"<p><strong>Background: </strong>Cardiac arrest in children is associated with high morbidity and mortality, primarily due to neurological injury. Biomarkers linked to brain injury, released into circulation from compromised elements of the neurovascular unit, act as significant prognostic indicators in patients suffering from hypoxic-ischemic brain injury (HIBI) subsequent to the restoration of spontaneous circulation (ROSC) after pediatric cardiac arrest. The aim of this systematic review and meta-analysis is to evaluate the prognostic utility of brain injury biomarkers in predicting neurological outcomes and survival in patients following cardiac arrest in the pediatric population.</p><p><strong>Methods: </strong>Bibliographic databases (PubMed, the Cochrane Library, and Embase) were searched from their inception to November 2024. A random-effect model was used for all analyses.</p><p><strong>Results: </strong>Our meta-analysis demonstrates significant associations between various biomarkers and survival or neurological outcomes after cardiac arrest. Neuron-specific enolase (NSE) levels were consistently elevated in non-survivors and patients with unfavorable neurological outcomes, with pronounced differences observed on Days 2 and 3 (e.g., Day 3 mean difference: -88.48, 95%CI: -146.77 to -30.19, P = 0.003). Emerging biomarkers, including UCH-L1 and GFAP, showed striking differences, such as elevated UCH-L1 levels on Day 1 (mean difference: -415.41, 95%CI: -474.41 to -356.61, P < 0.001) and GFAP levels exceeding 4000 ng/mL in non-survivors on Day 2 (P < 0.001).</p><p><strong>Conclusions: </strong>Our findings underscore the significant prognostic value of biomarkers in predicting survival and neurological outcomes following cardiac arrest. Neuron-specific enolase (NSE) consistently demonstrated its reliability across multiple time points, while emerging biomarkers like UCH-L1 and GFAP showed promising potential for early outcome stratification.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143588841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic and prognostic value of cystatin C in acute coronary syndrome: An up-to-date meta-analysis.","authors":"Michal Pruc, Damian Swieczkowski, Basar Cander, Milosz J Jaguszewski, Sagar Galwankar, Salvatore Di Somma, Fatimah Lateef, Indrani Sardesai, Ayman El-Menyar, Michal Zembala, Jacek Kubica, Togay Evrin, Burak Katipoglu, Zubaid Rafique, Frank William Peacock, Lukasz Szarpak","doi":"10.5603/cj.102453","DOIUrl":"10.5603/cj.102453","url":null,"abstract":"<p><strong>Background: </strong>The role of Cystatin C (CysC) in the diagnosis and prognosis of cardiovascular disease, particularly acute coronary syndrome (ACS), is increasingly significant. The goal of this meta-analysis was to assess the diagnostic and prognostic value of CysC in patients with ACS, as well as its association with major adverse cardiovascular events (MACE), defined as mortality, myocardial infarction, heart failure, and stroke.</p><p><strong>Methods: </strong>The present study is a systematic review and meta-analysis. Using PubMed, Web of Science, Cochrane Library, and Embase, a literature review of cohort and case control studies reporting MACE and using the terms ACS and Cystatin C was conducted, excluding studies published after August 1, 2024. the meta-analysis using a random effects model.</p><p><strong>Results: </strong>CysC concentrations were significantly higher in patients with ACS compared to controls [mean difference (MD) = 0.36, p < 0.001], and in acute myocardial infarction (AMI) vs. unstable angina (MD = 0.18, p < 0.001). No significant differences were observed between ST elevation myocardial infarction (STEMI) and Non-ST elevation myocardial infarction (NSTEMI). Patients with MACE had higher CysC levels than those without (MD = 0.25, p < 0.001). Hospital survivors had lower CysC levels compared to those who died (MD = -0.25, p < 0.001). Higher CysC concentrations were associated with increased risks of MACE, cardiac death, overall mortality, myocardial reinfarction, and stroke, both during hospitalization and beyond.</p><p><strong>Conclusions: </strong>CysC is a promising biomarker for both diagnosis and prognosis in patients with ACS, especially in the context of predicting MACE, mortality and heart failure risk. The use of CysC may improve risk stratification and support therapeutic decision-making in clinical practice.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of pre-existing comorbidities and complications with inpatient COVID-19 mortality - a single-center retrospective study.","authors":"Damian Palus, Martyna Gołębiewska, Olga Piątek-Dalewska, Krzysztof Grudziński, Krzysztof Kuziemski, Radosław Owczuk, Michał Hoffmann, Dariusz Kozłowski, Tomasz Stefaniak","doi":"10.5603/cj.103122","DOIUrl":"https://doi.org/10.5603/cj.103122","url":null,"abstract":"<p><strong>Background: </strong>This study evaluates the impact of pre-existing comorbidities and in-hospital complications on COVID-19 mortality rates.</p><p><strong>Methods: </strong>A retrospective single-center study was conducted using electronic health records from 640 COVID-19 patients hospitalized at the University Clinical Centre in Gdansk, Poland, between November 2020 and May 2021. Patients were categorized based on disease severity into stable or ICU wards based on the disease severity. Data on demographics, comorbidities, complications, and treatments were collected and verified. Statistical analyses, including odds ratios (ORs) and confidence intervals (CIs), assessed mortality risk factors supported by python-based processing.</p><p><strong>Results: </strong>The mean patient age was 67 years (SD ± 15.89), comprising 39% females (n = 250) and 60.94% males (n = 390). Mortality risk was highest in patients aged 65 years and older (OR 3.00; 95% CI, 1.97-4.60). Among the pre-existing comorbidities, chronic kidney disease (OR 3.28; 95% CI, 2.12-5.09), atrial fibrillation (OR 2.43; CI 95%, 1.63-3.61), and heart failure (OR 2.89; 95% CI, 1.91-4.37) were significant predictors of mortality. In hospital complications, such as severe respiratory failure requiring ICU ventilation (OR 23.59; 95% CI, 2.81-197.87), myocardial infarction (OR 25.43; 95% CI, 3.16-204.97), acute kidney injury requiring renal replacement therapy (OR 19.15; 95% CI, 6.49-56.51), sepsis (OR 7.22, 95% CI, 3.77-13.84), stroke, further increased mortality risk.</p><p><strong>Conclusions: </strong>COVID-19 patients with pre-existing renal and cardiovascular conditions face a higher risk of fatal outcomes. Early diagnosis and intervention targeting these complications are vital to in reducing mortality. Further research is needed to reconcile disparities with existing literature.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Galectin-3: Heart failure biomarker in pediatric heart defects.","authors":"Daniel Gondko, Patrycja Dębiec, Jakub Roman, Nikodem Pietrzak, Krzysztof Kocot, Jacek Kusa","doi":"10.5603/cj.99070","DOIUrl":"https://doi.org/10.5603/cj.99070","url":null,"abstract":"<p><p>Galectin-3 (Gal-3), a β-galactoside-binding lectin, has emerged as a potential diagnostic and prognostic biomarker for various diseases, including certain heart and kidney diseases, as well as cancer. Its significance is particularly notable in the context of congenital heart defects (CHD), which are the most prevalent congenital malformations, occurring in 6 to 8 out of every 1000 live births. Symptoms of heart failure (HF) in patients with congenital heart defects can manifest early in life, but in some cases, the disease progresses gradually, leading to a gradual decline in quality of life and the development of various complications. This variability underscores the need for early biomarkers to detect HF development in pediatric patients. Gal-3 plays a key role in myocardial remodeling, making it a promising candidate for advancing the diagnosis and management of HF in CHD patients. It is especially relevant in pediatric care, where early detection and intervention can significantly alter disease progression and patient outcomes. This review aims to consolidate current knowledge on the utility of Gal-3 in predicting HF among pediatric patients with CHD, highlighting its potential in changing the direction of diagnosis and treatment in this vulnerable patient population.</p>","PeriodicalId":93923,"journal":{"name":"Cardiology journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}